Fan Yu(范 昱， Shanghai Organ Transplant Clini Center，Dept Renal Transplant，Shanghai lst Peop Hosp，Shanghai 200080)…∥Chin J Transplant.－2011，32(8).－471～473

Urological malignancy in renal allograft recipients.，report of 22 clinical cases

Fan Yu(范 昱， Shanghai Organ Transplant Clini Center，Dept Renal Transplant，Shanghai lst Peop Hosp，Shanghai 200080)…∥Chin J Transplant.－2011，32(8).－471～473

ObjectiveTo investigate the incidence of urological malignancy in renal allograft recipients and explore the mechanism of increased incidence in China and the management.MethodsA retrospective study was performed on 22 patients with urological malignancy in renal allograft recipients between 1978 and 2010.ResultsTwenty－two cases of urological malignancy were diag-nosed by pathologic evidence，including 9 cases of transitional cell carcinoma(TCC)of bladder，1 case of squamous cell carcinoma of bladder，1 case of adenocarcinoma of bladder，1 case of TCC of pelvis，1 case of TCC of bladder and pelvis，1 case of TCC of ureter complicated with adenoearcinoma of bladder，2 cases of TCC of ureter，2 cases of TCC of ureter and bladder，3 cases of clear cell carcinoma of kidney，and 1 case of undifferentiated carcinoma of kidney.All the malignancies belonged to native organs.All the patients suffering bladder cancer had normal function of allograft.Five patients with TCC of pelvis or ureter survived and 2 cases died early after operation.All the patients suffering renal carcinoma deceased within 6 months after diagnosis.Oneyear survival rate was 73.7%after the diagnosis of urological malignancy.ConclusionUrological malignancy ranked highest in malignancy in renal allograft recipients，and rare pathological types of urological malignancy in non－renal allograft recipients are often demonstrated.The strategy of treatment should take consideration of the relationship between usage of immunosupressive agents and preservation of allograft function.It is critical for the therapy of malignancies to possess satisfactory allograft function.The prognosis of renal cell carcinoma is poor.10 refs.

(Authors)